Skip to main content

Advertisement

SpringerLink
Log in

Das Nierenzellkarzinom

Renal cell carcinoma

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Etwa 85% aller malignen Tumoren der Niere sind Nierenzellkarzinome (NZK). Die Sonographie ist die führende Untersuchung zur Früherkennung von Nierentumoren. In den letzten Jahren wurde die Therapie des NZK durch neue therapeutische Möglichkeiten, sowohl beim lokalisierten als auch beim metastasierten Tumor bereichert. Die Klassifikation des NZK erfolgt auf der Basis der TNM- und der UICC-Kriterien. Die sog. Motzer-Kriterien (MSKCC) werden zunehmend zur Abschätzung der Prognose, zur Therapieüberwachung und als Grundlage für Entscheidung der Art der systemischen Therapie herangezogen

Abstract

Approximately 85% of all malignant tumors of the kidney are renal cell carcinomas (RCC). Sonography is the leading examination for early detection of kidney tumors. The treatment of RCC has been enriched in recent years by new therapeutic options for localized and metastatic cancer. The classification of RCC is based on TNM and UICC criteria. The so-called Motzer criteria are being increasingly employed to assess prognosis and monitor therapy and as the basis for reaching decisions on choosing the type of systemic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Gesellschaft der epidemiologischen Krebsregister in Deutschland / Robert-Koch-Institut (2010) Krebs in Deutschland 2005–2006, Häufigkeiten und Trends: Niere, 6. Aufl. RKI, Berlin, S 80–83, http: / / www.ekr.med.uni-erlangen.de / GEKID

  2. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490

    Article  PubMed  CAS  Google Scholar 

  3. Ljungberg B, Hanbury DC, Kuczyk MA et al (2010) EAU Guidelines on renal cell carcinoma. Eur Urol 58:398–406

    Article  PubMed  Google Scholar 

  4. Lotan Y (2011) The future of nephron sparing procedures for renal masses: balancing costs, efficacy, patient outcomes and experience. J Urol 185:1560–1561

    Article  PubMed  Google Scholar 

  5. Gill IS, Aron M, Gervais DA, Jewett MA (2010) Clinical practice. Small renal mass. N Engl J Med 362:624–634

    Article  PubMed  CAS  Google Scholar 

  6. Fornara P, Doehn C, Seyfarth M, Jocham D (2000) Why is urological laparoscopy minimally invasive? Eur Urol 37:241–250

    Article  PubMed  CAS  Google Scholar 

  7. Nabi G, Cleves A, Shelley M (2010) Surgical management of localised renal cell carcinoma. Cochrane Database Syst Rev (3):CD006579

    Google Scholar 

  8. Breda A, Stepanian SV, Liao J et al (2007) Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe. J Urol 178:47–50

    Article  PubMed  CAS  Google Scholar 

  9. Blom JHM, Poppel H van, Maréchal JM et al (2009) Radical nephrectomy with and without lymph-node dissection: Final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55:28–34

    Article  PubMed  Google Scholar 

  10. Levy D, Avallone A, Jones JS (2010) Current state of urological cryosurgery: prostate and kidney. BJU Int 105:590–600

    Article  PubMed  Google Scholar 

  11. Coppin C, Le L, Porzsolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2):CD006017

    Google Scholar 

  12. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carinoma. N Engl J Med 356(2):125–134

    Article  PubMed  CAS  Google Scholar 

  13. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    Article  PubMed  CAS  Google Scholar 

  14. Motzer R, Hutson TH, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  PubMed  CAS  Google Scholar 

  15. Bellmunt J, Flodgren P, Roigas J et al (2009) Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int 104:10–18

    Article  PubMed  CAS  Google Scholar 

  16. Patard JJ, Pignot G, Escudier B et al (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. Eur Urol. [Epub ahead of print]

  17. Aaltomaa S, Lipponen P, Ala-Opas M et al (1997) Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 31:350–355

    PubMed  CAS  Google Scholar 

  18. Gunningham SP, Currie MJ, Han C et al (2001) Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61:3206–3211

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Universitätsklinik und Poliklinik für Urologie und Nierentransplantation, Martin-Luther-Universität Halle-Wittenberg, Ernst Grube-Straße 40, 06120, Halle, Deutschland

    P. Fornara & M.R. Hoda

Authors
  1. P. Fornara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.R. Hoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Fornara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fornara, P., Hoda, M. Das Nierenzellkarzinom. Urologe 50 (Suppl 1), 219 (2011). https://doi.org/10.1007/s00120-011-2677-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00120-011-2677-5

Schlüsselwörter

Keywords

Search

Navigation